Estabilidad microbiológica de medicamentos…
479
10.
Hessel H, et al. The genotoxic risk of hospital, pharmacy and medical personnel
occupationally exposed to cytostatic drugs-‐-‐evaluation by the micronucleus assay. Mutat
Res. 2001;497(1-‐2):101-‐9.
11.
Roth S, et al. Analysis of chromosomal aberrations, sister-‐chromatid exchanges and
micronuclei in peripheral lymphocytes of pharmacists before and after working with
cytostatic drugs. Mutat Res. 1994;325(4):157-‐62.
12.
McDiarmid MA, et al. Chromosome 5 and 7 abnormalities in oncology personnel handling
anticancer drugs. J Occup Environ Med. 2010;52(10):1028-‐34.
13.
Dranitsaris G, et al. Are health care providers who work with cancer drugs at an increased
risk for toxic events? A systematic review and meta-‐analysis of the literature. J Oncol
Pharm Pract. 2005;11(2):69-‐78.
14.
Sauere-‐Cubizolles MJ, et al. Ectopic pregnancy and occupational exposure to antineoplastic
drugs. Lancet. 1993; 341: 1169-‐71.
15.
Hansen J, et al. Cancer morbidity among Danish female pharmacy technicians. Scand J
Work Environ Health. 1994;20(1):22-‐6.
16.
Valanis BG, et al. Association of antineoplastic drug handling with acute adverse effects in
pharmacy personnel. Am J Hosp Pharm. 1993;50(3):455-‐62.
17.
Chaffee BW, et al. Guidelines for the safe handling of hazardous drugs: consensus
recommendations. Am J Health Syst Pharm. 2010;67(18):1545-‐6.
18.
International Society of Oncology Pharmacy Practicioners Standards Committee. ISOPP
standards of practice. Safe handling of cytotoxics. J Oncol Pharm Pract. 2007;13 Suppl:1-‐
81.
19.
National I
ealth. Preventing occupational exposure to
antineopla
ealth care settings. NIOSH publication nº
2004-‐165.
(acceso diciembre 2011).
20.
Sessink P,
zardous drug containment system. Hosp
Pharm. 1999; 34: 1311-‐7.
21.
Connor T, et al. Effectiveness of a closed-‐system device in containing surface
contamination with cyclophosphamide and ifosfamide in an I.V. admixture area. Am J
Health Syst Pharm. 2002; 59: 68-‐72.
22.
Harrison B, et al. Comparison of surface contamination with cyclophosphamide and
fluorouracil using a closed-‐system drug transfer device versus standard preparation
techniques. Am J Health Syst Pharm. 2006; 63: 1736-‐44.
23.
Siderov J, et al. Reducing workplace cytotoxic surface contamination using a closed-‐system
drug transfer device. J Oncol Pharm Pract. 2010;16(1):19-‐25.
24.
Yoshida J, et al. Use of a closed system device to reduce occupational contamination and
exposure to antineoplastic drugs in the hospital work environment. Ann Occup Hyg.
2009;53(2):153-‐60.
25.
Vandenbroucke J, et al. How to protect environment and employees against cytotoxic
agents, the UZ Ghent experience. J Oncol Pharm Pract. 2001; 6: 146-‐152.
26.
United States Pharmacopeia, Inc. U.S. Pharmacopeia 27. Chapter <797>: Pharmaceutical
Compounding -‐ Sterile Preparations. Rockville, MD: United States Pharmacopeial
Convention, 2004;2461-‐77.
27.
Wilson JP, et al. Aseptic technique as a safety precaution in the preparation of
antineoplastic agents. Hosp Pharm. 1981;16(11):575-‐6, 579-‐81.
28.
De Prijck K, et al. Microbiological challenge of four protective devices for the
reconstitution of cytotoxic agents. Lett Appl Microbiol. 2008;47(6):543-‐8.
29.
McMichael D, et al. Utility of the PhaSeal closed system drug transfer device. The American
Journal of Pharmacy Benefits. 2011;3(1): 9-‐16.
